Details for Patent: 10,239,883
✉ Email this page to a colleague
Which drugs does patent 10,239,883 protect, and when does it expire?
Patent 10,239,883 protects CALQUENCE and is included in two NDAs.
This patent has eighty-two patent family members in forty-one countries.
Summary for Patent: 10,239,883
| Title: | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
| Abstract: | The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. |
| Inventor(s): | Barf; Tjeerd A. (Ravenstein, NL), Jans; Christiaan Gerardus Johannes Maria (Cuijk, NL), de Man; Adrianus Petrus Antonius (Hurwenen, NL), Oubrie; Arthur A. (Wijchen, NL), Raaijmakers; Hans C. A. (Eindhoven, NL), Rewinkel; Johannes Bernardus Maria (Berghem, NL), Sterrenburg; Jan Gerard (Renkum, NL), Wijkmans; Jacobus C. H. M. (Oss, NL) |
| Assignee: | Merck Sharp & Dohme B.V. (Haarlem, NL) |
| Application Number: | 15/668,385 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,239,883 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 10,239,883
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | CALQUENCE | acalabrutinib | CAPSULE;ORAL | 210259-001 | Oct 31, 2017 | RX | Yes | Yes | 10,239,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB | ⤷ Subscribe | ||||
| Astrazeneca | CALQUENCE | acalabrutinib | CAPSULE;ORAL | 210259-001 | Oct 31, 2017 | RX | Yes | Yes | 10,239,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Subscribe | ||||
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | 10,239,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Subscribe | ||||
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | 10,239,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,239,883
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 11174578 | Jul 19, 2011 | |
International Family Members for US Patent 10,239,883
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2734522 | ⤷ Subscribe | 301097 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2734522 | ⤷ Subscribe | PA2021004 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2734522 | ⤷ Subscribe | CA 2021 00007 | Denmark | ⤷ Subscribe |
| European Patent Office | 2734522 | ⤷ Subscribe | LUC00202 | Luxembourg | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
